Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Paclitaxel in Women of African Ancestry With Metastatic TNBC
NCT07528768Phase 2Not yet recruiting
- Sponsor
- The University of the West Indies
- Start
- Jun 2027
- Primary completion
- Jun 2034
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by The University of the West Indies. Primary endpoint: Progression-Free Survival at 5 years. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07528768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528768.